Latest Natalizumab Stories
Cimzia(R) (certolizumab pegol) now offered in an innovative prefilled syringe designed in partnership with OXO GOOD GRIPS(R) ATLANTA, May 15 /PRNewswire/ --- UCB today announced that Cimzia(R) (certolizumab pegol), the only PEGylated anti-TNF (Tumor Necrosis Factor) approved in the U.S.
- Available this week, Cimzia(R) (certolizumab pegol), the only pegylated anti-TNF, offers a new treatment option for U.S.
Multiple sclerosis patients may benefit from the drug fampridine.
Aurora St. Luke's Medical Center Discovers Way to Fight Rare, but Deadly, Side Effect from Drug. MILWAUKEE, Feb. 18 /PRNewswire/ -- Researchers at Aurora St.
Tysabri is Decision Resources' Gold Standard Through 2017 for Relapsing-Remitting Multiple Sclerosis, According to a New Report from Decision Resources WALTHAM, Mass., Feb.
On Monday, Biogen Idec Inc said it notified regulators of a new case of a potentially deadly brain disease in a patient being treated with its Tysabri multiple sclerosis drug, the fourth such case reported globally this year.
Increased Uptake of Current Agents and Emergence of New Therapies Will Drive Robust Annual Market Growth, According to a New Report from Decision Resources WALTHAM, Mass., Dec.
On Monday Italian researchers said a faulty immune reaction may be responsible for the development of epilepsy.
PatientsLikeMe, the leading online community for patients with life-changing conditions, announces the release of its newest PatientsLikeMeListen(TM) report: "Did the July 2008 PML announcement affect the Tysabri brand?" Among its findings, the report reveals that patients retained an overall positive perception of the Tysabri brand despite the July 2008 announcement of two additional PML cases.
Biogen Idec Inc. says a U.S. woman contracted a deadly brain infection while taking the drug Tysabri.
- A morbid dread of being buried alive. Also spelled 'taphiphobia'.